Pharmacovigilance practice among pediatric neurologists from Poland and Germany

BMC Medical Education

Research

Jędrzej Fliciński¹  Karolina Hoffmann²  Wiesław Bryl²  Izabela Niśkiewicz³  Agnieszka Koligat-Seitz⁴  Krzysztof Kus⁵  Tomasz Zaprutko⁵  Dorota Kopciuch⁵  Anna Paczkowska⁵  Piotr Ratajczak⁵  Elżbieta Nowakowska⁶ 

[1] Department of Developmental Neurology, Poznan University of Medical Sciences, Poznan, Poland;Department of Internal Diseases, Metabolic Disorders and Arterial Hypertension, Poznan University of Medical Sciences, Poznan, Poland;Department of Neurology, Martin-Luther-University Hospital Halle- Wittenberg, Halle, Germany;Department of Otolaryngology, Greater Poland Pediatric Center, Poznan, Poland;Department of Pharmacoeconomics and Social Pharmacy, Poznan University of Medical Sciences, Rokietnicka 7 St, 60-806, Poznań, Poland;Department of Pharmacology and Toxicology Institute of Health Sciences, Collegium Medicum, University of Zielona Gora, Góra, Poland;

关键词: Pharmacovigilance;    Epilepsy;    Children with epilepsy;    Adverse drug reactions;    Drug safety;    Neurologists’ knowledge;    Poland;    Germany;   

DOI  :  10.1186/s12909-023-04542-4

 received in 2023-05-16, accepted in 2023-07-27,  发布年份 2023

来源: Springer

【 摘 要 】

ObjectivesTo compare the pediatric neurologists’ knowledge, practice, and barriers to the pharmacovigilance (PV) process in Poland and Germany.MethodsThe research tool was an online anonymous questionnaire on Google Forms e-mailed to pediatric neurologists from Poland and Germany.ResultsThe questionnaires were handed out to 830 pediatric neurologists and 371 expressed their consent to participate in the study. Most of the neurologists were familiar with the definition of PV and adverse drug reactions (ADRs). Only 34.10% of pediatric neurologists from Poland, and 38.88% from Germany believe that many ADRs are preventable and almost most of them believe it is necessary to report ADRs from children with epilepsy. Unfortunately, in opposite to this knowledge, only 37.79% of respondents from Poland and 40.32% from Germany felt co-responsible for reporting ADRs. The main reason for the neurologists not to report ADRs was a conviction that reporting ADRs would be an additional burden generating extra work.ConclusionThere is no big difference between the practice of PV by pediatric neurologists in Poland and Germany. System-regulated PV stabilization in the country translates into the practice of maintaining PV. Monitoring the safety of pharmacotherapy and knowledge of risks associated with ADRs should be included in the curricula of academic neurologics courses.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 6